Drug
Radium-223 clinical trials
Also written Radium-223 and BAY 88-8223.
A product of Radium; its studies count on that page too.
- studies test it
- 16
- open now
- 1
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the Radium-223 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
16 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 10
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 16
Memorial Sloan Kettering Cancer Center (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Utah (1) · National Cancer Institute (NCI) (1) · University of California, San Francisco (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Peter MacCallum Cancer Centre, Australia (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1)
Often tested with
Tested in the same studies.
Docetaxel (2) · Nivolumab (1) · Dexamethasone (1) · Enzalutamide (1) · Darolutamide (1) · Atezolizumab (1)
Studies
Open first, then newest update. How each study uses Radium-223 is read from its arms, and is right about nine times in ten.
Testing it · 16
- Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate CancerNot yet recruitingPhase 2Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARDNCT07717099Written as Ra223
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate CancerActive, not recruitingPhase 1University of UtahNCT04109729Written as Radium-223
- A Study to Test Radium-223 With Docetaxel in Patients With Prostate CancerActive, not recruitingPhase 3Memorial Sloan Kettering Cancer CenterNCT03574571Written as Radium-223
- Radium-223 in Combination With EnzalutamideCompletedPhase 2Cancer Trials IrelandNCT02225704Written as Radium-223 and enzalutamide
- Radium-223 in Biochemically Recurrent Prostate CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT04206319Written as Radium-223
- Efficacy of Ra-223 in PSMA PET Optimally Selected PatientsActive, not recruitingPhase 2University of California, San FranciscoNCT05924672Written as Radium-223
- RAdium-223 and SABR Versus SABR for Oligometastatic Prostate CancersCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04037358Written as Radium-223
- Phase III Radium 223 mCRPC-PEACE IIIActive, not recruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT02194842Written as Ra223
- Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT05383079Written as Radium-223
- Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 StatusCompletedPhase 2MedSIRNCT03002220Written as radium-223
- Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 2Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT03230734Written as Radium-223
- Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPCActive, not recruitingPhase 4University Health Network, TorontoNCT03432949Written as Dexamethasone plus Radium-223
- Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPCWithdrawnPhase 3GenesisCare USANCT05771896Written as Radium-223
- Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT02278055Written as Radium-223
- Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02463799Written as Radium-223
- Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based ChemotherapyTerminatedEarly Phase 1University of Michigan Rogel Cancer CenterNCT03208712Written as Radium-223
Given in every arm · 3 — Radium-223 is usual care beside what is tested
- A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the BonesCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT05133440Written as Radium dichloride
- Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPCCompletedPhase 2Dana-Farber Cancer InstituteNCT03093428Written as Radium-223
- Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone MetsCompletedPhase 1Dana-Farber Cancer InstituteNCT02406521Written as Radium-223
As the comparator · 1 — what is tested is compared with Radium-223
Codes
What other systems call Radium-223 · ClinicalTrials.gg INT000627
- MeSH (NLM) C000615150Radium-223Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8BR2SOL3L1RADIUM RA-223Confirmed FDA, NLM, Wikidata
- Wikidata Q18888805radium-223Confirmed FDA, NLM, Wikidata
- DrugBank DB12813One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615150 | Radium-223 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8BR2SOL3L1 | RADIUM RA-223 | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q18888805 | radium-223 | Confirmed FDA, NLM, Wikidata |
| DrugBank | DB12813 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.